Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents
Open Access
- 31 December 2017
- journal article
- research article
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 19 (4) , 395-402
Abstract
Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD. Though not FDA-approved, methylphenidate and guanfacine are effective for the management of hyperactivity in children with ASD. Selective serotonin reuptake inhibitors are often used in clinical practice to target anxiety and compulsions; however, there is little evidence to support its use in this population. There is a great need for further research on the safety and efficacy of existing psychotropic medications in youth with ASD, as well as the development of new treatment modalities for the core and associated behavioral symptoms.Keywords
This publication has 81 references indexed in Scilit:
- A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disordersBMC Psychiatry, 2013
- Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trialInternational Journal of Neuropsychopharmacology, 2013
- Effect of Aripiprazole 2 to 15 mg/d on Health-Related Quality of Life in the Treatment of Irritability Associated with Autistic Disorder in Children: A Post Hoc Analysis of Two Controlled TrialsClinical Therapeutics, 2012
- Low-Dose Quetiapine for Adolescents With Autistic Spectrum Disorder and Aggressive BehaviorClinical Neuropharmacology, 2011
- Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic DisorderThe Journal of Clinical Psychiatry, 2011
- Possible Influence of Variant of the P-Glycoprotein Gene ( MDR1/ABCB1 ) on Clinical Response to Guanfacine in Children with Pervasive Developmental Disorders and HyperactivityJournal of Child and Adolescent Psychopharmacology, 2010
- Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum DisordersNeuropsychopharmacology, 2009
- Psychiatric Disorders in Children With Autism Spectrum Disorders: Prevalence, Comorbidity, and Associated Factors in a Population-Derived SampleJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- Use of clonidine in children with autism spectrum disordersBrain and Development, 2008
- Topiramate in children with autistic spectrum disordersBrain and Development, 2006